MedTrace Logo

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

NCT00837291 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-02-01

No results posted yet for this study

Summary

This study will test the effectiveness of CF101 in treating the symptoms of osteoarthritis (OA) of the knee. Eligible patients will be given either CF101 or matching placebo tablets and their symptoms will be evaluated over the 12 week treatment period.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

CF101

CF101 tablets 1 mg BID

DRUG

Placebo

Placebo tablets BID

Sponsors & Collaborators

  • Can-Fite BioPharma

    lead INDUSTRY

Principal Investigators

  • Michael H Silverman, MD · Can-Fite BioPharma Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2018-12-31
Completion
2019-01-31
FDA Drug
Yes

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837291 on ClinicalTrials.gov